Ezetimibe Utilization Early After Acute Myocardial Infarction, "EzAMI Trial"
Rationale: Patients with acute coronary syndromes are at an increased risk for recurrent adverse coronary events, particularly during the early period following their initial presentation. Early (in-hospital) initiation of high-intensity statins reduces the risk of recurrent events and is therefore recommended by the b
| Condition(s) | Acute Myocardial Infarction, Dyslipidemias |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Rationale: Patients with acute coronary syndromes are at an increased risk for recurrent adverse coronary events, particularly during the early period following their initial presentation. Early (in-hospital) initiation of high-intensity statins reduces the risk of recurrent events and is therefore recommended by the best current practice guidelines.(1,2) However, the delayed onset of action of statin therapy and given the frequent failure of patients to achieve the recommended LDL-C targets using statins alone (as per the current practice guidelines recommendations), might be placing large number of patients at increased risk during such a vulnerable period early after an ACS.(3) More rapid and effective reduction of LDL-C levels using combination therapy from the outset may therefore be |
| Who can participate | Inclusion Criteria: * Age more than 18 years. Both genders are eligible. * Acute myocardial infarction (STEMI or NSTEMI) within 48 hours from the onset of symptoms. * Baseline LDL-C above 125 mg/dl for those who were not on consistent lipid lowering therapy; or above 100 mg/dl for those who were compliant (≥ 90 days) on moderate intensity statin therapy. Exclusion Criteria: * Refusal to participate in the study. * Proved intolerance to statins on previous use. * Having conditions (or taking medications) that would not allow concomitant safe statins use. \[such as patients receiving Cyclosporine - Gemfibrozil -Pazopanib - Tipranavir - Itraconazole - Ketoconazole\] * Those who are already compliant on high intensity statins. * Those who are already on statins plus non-statin agent (ezetimibe |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Lead sponsor | Cairo University |
| Locations | Aswān, Egypt |
| Start date | 2021-03-24 |
| NCT ID | NCT04701242 |
| Official listing | https://clinicaltrials.gov/study/NCT04701242 |